You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Response to: ‘Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’’ by Smerilli et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’’ by Smerilli et al
  1. Roberta Priori1,2,
  2. Greta Pellegrino1,
  3. Serena Colafrancesco1,
  4. Cristiano Alessandri1,
  5. Fulvia Ceccarelli1,
  6. Manuela Di Franco1,
  7. Valeria Riccieri1,
  8. Rossana Scrivo1,
  9. Antonio Sili Scavalli1,
  10. Francesca Romana Spinelli1,
  11. Fabrizio Conti1
  1. 1 Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari - Reumatologia, Università degli Studi di Roma La Sapienza, Roma, Italy
  2. 2 Saint Camillus International University of Health Science, UniCamillus, Rome, Italy
  1. Correspondence to Dr Greta Pellegrino, Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari - Reumatologia, Università degli Studi di Roma La Sapienza, Roma, Italy; greta.pellegrino{at}uniroma1.it

https://doi.org/10.1136/annrheumdis-2021-220612

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the comments by Smerilli et al 1 in response to our letter2 about the willingness to vaccination among patients with rheumatic and musculoskeletal diseases (RMDs).

    By the time we had performed our survey, only the Pfizer–BioNTech vaccine was available for the administration to healthcare personnel, therefore we could not assess whether, among the reasons for refusal, the kind of vaccine might have affected willingness to vaccinate. After some months, once other vaccines became available, Smerilli et al, confirming a rate of acceptance to COVID-19 vaccination similar to ours, had the opportunity to observe that the decision of accepting or declining vaccination is heavily influenced by the type of vaccine.

    We can now …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors RP and GP drafted and revised the response letter. SC, FC, VR, RS, FRS, CA, MDF, ASS and CF revised the paper.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles